News – Page 816 – Endpoints News

Bristol Myers Squibb commits $300 million to combat racial disparities, but declines to release own demographic data

5 years ago

Roche pulls a tumor micro-environment drug out of the freezer, hands it to a UK upstart

5 years ago

Covid-19 roundup: Researchers call out Gilead for diversity of remdesivir trials in NEJM; Mexico in vaccine dose, ...

5 years ago

Martin Shkreli's infamous Daraprim falls off top 20 most expensive drugs list

5 years ago

Novo backs 'breakthrough' antifungal player's $60M round — with a focus on rare mold infections

5 years ago

Moderna offers steep discount in US supply deal — but still takes the crown with close to $2.5B in vaccine ...

5 years ago

Harmony Biosciences sets terms on $100M IPO; FDA accepts a Protalix BLA for review

5 years ago

Fulcrum stumbles in PhII of old GSK drug, sending shares tumbling

5 years ago

Eisai is creating a new US corporate, R&D HQ in Roche’s old Nutley, NJ campus

5 years ago

FDA gives thumbs-down on hearing loss drug, citing manufacturing issues, and sends Fennec stock reeling

5 years ago

Plotting to be the BridgeBio of AI, Atomwise lands $123 million Series B for hype-heavy platform

5 years ago

Endpoints News ranks the top 57 players in the Covid-19 vaccine race. Here's how it stacks up today

5 years ago

Perceptive births its first in-house startup — and it's a China play

5 years ago

Ligand scoops up Pfenex for up to $516M, adding proteins to their antibody chickens and delivery tech

5 years ago

Firdapse fails PhIII for myasthenia gravis as Catalyst keeps looking for expanded label

5 years ago

Covid-19 roundup: Pfizer-backed BioNTech plans to seek FDA OK for a new vaccine 'as early as' October — ahead of ...

5 years ago

Hunting a blockbuster, Bayer forges an $875M-plus M&A deal to acquire women’s health biotech

5 years ago

Reata suggests Friedreich's ataxia program could be delayed, sending stock plunging

5 years ago

Vida Ventures co-leads Dyne's $115M megaround for next-gen oligo therapies aimed squarely at muscles

5 years ago

Eli Lilly teams with Pieris on HER2+ tumors; Opdivo + Yervoy best chemo in mesothelioma

5 years ago

Innovent and Eli Lilly challenge Merck's mega-blockbuster Keytruda in non-small cell lung cancer field

5 years ago

AnaptysBio's etokimab provides more disappointing results, raising questions about compound's future

5 years ago

Spark Therapeutics nabs new CMO from Genentech, filling a major post-merger departure

5 years ago

The duvelisib hot potato is tossed to a new owner as Verastem looks to reorganize around the pipeline

5 years ago

First page Previous page 813 814 815816817 818 819 Next page Last page